Merck Reports Decline in Q4 Earnings; Beats Estimates (MRK)

Merck Reports Decline in Q4 Earnings; Beats Estimates (MRK)

RSS

Health care company, Merck & Co., Inc.(MRK) saw a drop in earnings for the Q4, but beat analysts estimates on Wednesday.

The Whitehouse Station, NJ based company reported fourth quarter earnings of $1.4 billion, or 46 cents per share, down from $1.51 billion, or 49 cents per share last year. On a non-GAAP basis, earnings came in at $2.54 billion, or 83 cents per share, beating analysts estimate of 81 cents per share.

Revenue for the quarter came in at $11.74 billion, down -5% from $12.29 billion last year, but beating analysts expectation of $11.48 billion.

Sales were affected by an unfavorable foreign exchange, but were partially offset by strong sales and growth of key products during the quarter.

Looking ahead, MRK expects to see FY2013 earnings in the range of $3.60 and $3.70 per share. Revenue is expected to see a 1-2% downside for the year.

Analysts expect to see EPS of $3.68 and revenue of $45.61 billion.

Merck & Co shares were down -$1.25, or -2.89% during premarket trading Friday. The stock has increased 12% in the past year.

The Bottom Line
Shares of Merck & Co., Inc.(MRK) have a 3.98% yield, based on Thursday’s closing price of $43.25.

Merck & Co., Inc.(MRK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from Dividend.com.

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today